A Phase II Study of the Association of Glivec (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta [platelet derived growth factor receptor-beta] or C-Kit
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Gemcitabine (Primary) ; Imatinib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 14 Nov 2007 New trial record.